Clinical Investigation of Human Parvovirus B19 Infection After Renal Transplantation in China

• Published in: Transplantation proceedings Vol. 45; no. 4; pp. 1593 - 1599
• Main Authors: Xiao, C, Wang, C.X, Liu, L.S, Fu, Q
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2013
• Subjects: Adult; Base Sequence; Case-Control Studies; China; DNA Primers; DNA, Viral - blood; Female; Humans; Kidney Transplantation; Male; Middle Aged; Parvoviridae Infections - diagnosis; Parvoviridae Infections - drug therapy; Parvoviridae Infections - physiopathology; Parvovirus B19, Human - genetics; Parvovirus B19, Human - isolation & purification; Surgery; China
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2013.02.040

Abstract Objective We investigated the incidence of human parvovirus B19 (HPV B19) infection after renal transplantation as well as the risk of anemia and renal allograft damage among infected transplant recipients in China. Methods We selected 114 patients at 1–18 months after renal transplantation for detection of HPV B19 DNA copies compared with a control population. Renal function and hematopoiesis were compared between infected and noninfected groups. Results Twenty-seven patients diagnosed with HPV B19 infection during follow-up (18.75%),which was a significantly higher number than among the general population over the same period. Infected versus nonaffected patients exhibited a significantly higher incidence of anemia and urinary abnormalities in addition to significantly lower values of hemoglobin, higher serum creatinine concentrations, and lower glomerular filtration rates. The 2 groups did not differ in the types or doses of calcineurin inhibitor (CNI) immunosuppressants. Two cases of pure red cell aplasia (PRCA) as confirmed using bone marrow biopsy, were observed in the infected group. They displayed HPV B19 DNA copy numbers >107 /mL and segmental mesangial cell proliferation on renal biopsy. The PRCA cases were cured with immunomodulatory therapy. Conclusions The HPV B19 infection rate was significantly higher among renal transplant recipients than normal controls. Infections correlated with damage to the renal allograft, which may in turn cause PRCA. Immunomodulation therapy was effective to treat this complication of HPV B19 infection.